🧬 biology

Determining the metabolic profile measured using ultra-high pressure liquid chromatography associated with Beta Amyloid burden in the brain in individuals with mild cognitive impairment

This study analyzes UPLC-based metabolic profiles from 59 individuals with mild cognitive impairment to identify seven specific metabolites, particularly Methionine Sulfoxide, that correlate with beta-amyloid burden and could serve as early biomarkers for Alzheimer's disease progression.

Original authors: Marjan Falahati, Elham Ramezannejad, Yosra Vaez-Gharamaleki, Parastoo Radnia, Saman Shahba, Pegah Rasoulian, Sara Rezaei, Negin Dasmeh, Maryam Bemanalizadeh

Published 2026-07-31

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Marjan Falahati, Elham Ramezannejad, Yosra Vaez-Gharamaleki, Parastoo Radnia, Saman Shahba, Pegah Rasoulian, Sara Rezaei, Negin Dasmeh, Maryam Bemanalizadeh

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your brain is a bustling, high-tech city. For this city to run smoothly, it needs a constant supply of energy and building materials, delivered by a complex network of roads and trucks. These materials are called metabolites—tiny chemical messengers and fuel sources like amino acids and fats that keep your brain cells alive and firing. Now, imagine a slow, invisible fog called beta-amyloid starting to clog the city's main intersections. This fog is the hallmark of Alzheimer's disease. Long before the city's traffic gridlock becomes obvious (which is when people start forgetting things), the fog begins to build up. Scientists have a special camera, a PET scan, that can take a picture of this fog, but it's expensive and hard to use on everyone. So, the big question is: Can we look at the city's "delivery trucks" (the blood) to see if the fog is coming, without needing the big camera? This is the detective work of metabolomics—studying the chemical fingerprints in our blood to predict what's happening deep inside the brain.

The Detective Work: Checking the Blood for Clues

In this study, a team of researchers decided to play detective. They wanted to see if they could find a link between the "fog" (beta-amyloid) in the brain and the chemical cargo in the blood of people who were just starting to show signs of memory trouble, a stage called Mild Cognitive Impairment (MCI). They didn't invent new tools; instead, they used a super-sensitive scanner called Ultra-High Pressure Liquid Chromatography (UPLC). Think of UPLC as a high-speed train station where thousands of tiny chemical packages (metabolites) are sorted and weighed with incredible precision.

The team pulled data from a massive global project called ADNI, looking at 59 people with an average age of about 69 years. They had two main pieces of information for each person: a PET scan score showing how much amyloid fog was in their brain, and a blood sample showing their levels of various metabolites. They ran the numbers to see which chemical packages in the blood seemed to be shouting, "Hey! The fog is getting worse!"

The Seven Suspects

After crunching the data, the researchers found seven specific metabolites that seemed to have a strong connection to the amount of amyloid fog in the brain. These were:

DOPA (a precursor to dopamine)
Methionine Sulfoxide (Met.SO)
Tryptophan Betaine
Choline
Leucine
Valine
FA (18:2) (a type of fatty acid)

When the researchers looked at these chemicals on their own, without worrying about how much time had passed, all seven showed a statistically significant link to the amyloid levels. It's like finding seven different smoke signals that all point to the same fire.

The Time Travel Twist

However, the story gets a little more interesting when the researchers added time into the mix. They wanted to know: Do these chemicals change as the disease gets worse over time? They used a special mathematical model to track how the levels of these chemicals moved alongside the amyloid fog over the study period.

Here is the plot twist: When they factored in the time interaction, only one of the seven suspects remained a strong, statistically significant predictor. That one was Methionine Sulfoxide (Met.SO).

The paper suggests that while the other six chemicals are definitely linked to the presence of the amyloid fog, Met.SO is the one that seems to be actively changing in a way that tracks with the progression of the disease over time. The researchers noted that Met.SO is particularly relevant when considering how the disease evolves. In fact, they found that Met.SO had a strong connection to the amyloid scores even after adjusting for time, with a p-value of 0.017 for the time interaction, making it a standout candidate for a "progression marker."

What the Paper Rules Out (and What It Doesn't)

It's important to know what this study didn't find, too. The researchers tested Cortisol (a stress hormone) and found that, despite what some other studies might suggest, it did not have a clear, significant predictive value for the amyloid fog in this specific group of people. Similarly, while Dopamine (related to DOPA) showed a link to the amyloid levels on its own, the study found that its interaction with time was not significant (p-value 0.871). This suggests that while dopamine levels are different in these patients, they might not be the best indicator for watching the disease get worse over time in the same way Met.SO might be.

The Bottom Line

The researchers are careful not to call this a "cure" or a "final answer." Instead, they suggest that these findings point toward a new way of looking at Alzheimer's. They propose that Methionine Sulfoxide is a particularly promising clue for understanding how the disease moves forward. The study suggests that by monitoring these specific metabolic changes, we might be able to spot the progression of Alzheimer's earlier or track it more closely than before.

However, the authors admit their detective work has limits. They worked with a relatively small group of 59 people, and they couldn't fully account for every possible factor like gender differences or environmental influences. They emphasize that these results suggest a path forward, but future studies with larger groups are needed to confirm if these chemical signals are truly reliable guides for the journey ahead. For now, the study offers a hopeful hint: the blood might hold a secret map to the brain's fog, and Met.SO looks like a very important landmark on that map.

Technical Summary: Metabolic Profiles and Beta-Amyloid Burden in Mild Cognitive Impairment

Problem Statement
Alzheimer's disease (AD) is a progressive neurodegenerative disorder where current diagnostic methods often fail to identify the condition at a stage where intervention could be most effective. A significant gap exists between the deposition of beta-amyloid (Aβ) plaques and the emergence of cognitive deficits. While Positron Emission Tomography (PET) using radio ligands allows for the non-invasive quantification of Aβ burden, there is a need to identify early metabolic biomarkers that correlate with this pathology. This study addresses the challenge of linking specific metabolic profiles, measured via blood samples, to whole-brain Aβ burden in individuals with Mild Cognitive Impairment (MCI), aiming to uncover potential biomarkers for disease progression.

Methodology
The research utilized a retrospective analysis of data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The study cohort consisted of 59 participants diagnosed with MCI.

Data Acquisition:
- Neuroimaging: Whole-brain standardized uptake value ratio (SUVR) maps and Centiloid (CL) values were derived from florbetapir PET scans to quantify Aβ burden. Data was normalized using the cerebellar grey and white matter as a reference.
- Cognitive Assessment: Cognitive function was evaluated using the Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-cog), and Mini-Mental State Examination (MMSE).
- Metabolomics: Blood metabolite levels were measured using Ultra-High-Performance Liquid Chromatography (UPLC) coupled with tandem mass spectrometry (MS/MS). The Biocrates MxP Quant 500 kit was employed to quantify hundreds of metabolites, including amino acids, lipids, and other biochemical classes.
Statistical Analysis:
- Feature Selection: An F-regression highlight determination strategy (from the scikit-learn library) was used to identify the most pertinent metabolites for predicting amyloid PET scores.
- Longitudinal Modeling: Linear mixed-effects models (LMM) were constructed to analyze the relationship between baseline metabolic data and changes in amyloid PET scores over time. These models adjusted for fixed effects (age, sex, time, metabolite levels) and included random effects for participant intercepts and time slopes.
- Interaction Analysis: Models were run both with and without time-metabolite interaction terms to assess how metabolic predictors influence PET scores dynamically.
- Significance: Statistical significance was defined as $p < 0.05$ , with effect sizes calculated using $R^2$ values relative to a base model.

Key Results
The analysis identified a set of metabolites with significant predictive value for amyloid PET scores.

Top Predictive Metabolites: Ten metabolites showed statistical significance in predicting PET scores. These included Dopamine, Methionine Sulfoxide (Met.SO), Tryptophan Betaine, Hypoxanthine, Choline, Cortisol, FA(18:2), FA(18:1), Valine, and Leucine.
Time Interaction Findings:
- When analyzing metabolites independently (without time interaction), seven metabolites demonstrated substantial predictive value: DOPA, Methionine Sulfoxide (Met.SO), Tryptophan Betaine, Choline, Leucine, Valine, and FA (18:2).
- When the interaction between time and metabolite levels was included in the model, Methionine Sulfoxide (Met.SO) remained the only metabolite with statistically significant predictive power ( $p = 0.017$ for the interaction term).
Specific Metabolite Observations:
- Methionine Sulfoxide (Met.SO): Showed a strong association with Aβ load, particularly when considering the temporal progression of the disease.
- Dopamine: Exhibited significant predictive value independently but lost significance when time interaction was considered, suggesting its levels may alter later in disease progression or correlate more with cognitive impairment than Aβ pathology itself.
- Choline, Leucine, and Valine: Showed significant independent predictive values but did not maintain significance in the time-interaction models.
- Lipids (FA 18:1 and 18:2): While FA(18:2) showed independent predictive value, neither fatty acid maintained significance when time interaction was accounted for.

Significance and Claims
The paper claims that metabolic alterations, specifically involving amino acids and lipids, are linked to the accumulation of beta-amyloid in the brains of individuals with MCI.

Biomarker Potential: The study suggests that the identified seven metabolites (DOPA, Met.SO, TrpBetaine, Choline, Leu, Val, and FA 18:2) could serve as early indicators of AD progression.
Role of Met.SO: The authors highlight Methionine Sulfoxide as particularly relevant. They note that Met.SO is a product of oxidative stress on methionine residues within Aβ plaques. The study posits that the persistence of Met.SO as a significant predictor even after adjusting for time interaction underscores its potential role in the pathological mechanism of AD, potentially reflecting oxidative stress and the downregulation of methionine sulfoxide reductase (MRS).
Therapeutic Implications: The authors suggest that understanding these metabolic alterations could pave the way for incorporating specific metabolites into therapeutic strategies targeting the illness's progression.
Limitations: The authors modestly acknowledge limitations, including the small sample size (59 subjects), the lack of gender-specific analysis, and the challenges of establishing causality due to the observational nature of the ADNI data. They emphasize that these findings require validation in larger, more diverse longitudinal cohorts.

In conclusion, the study provides evidence of a correlation between specific blood-based metabolic profiles and brain amyloid burden, proposing that Met.SO, in particular, may be a robust biomarker for tracking AD progression in the MCI stage.